Spleen tyrosine kinase inhibition attenuates autoantibody production and reverses experimental autoimmune GN

Journal of the American Society of Nephrology

Volumn 25, Issue 10, 2014, Pages 2291-2302

  McAdoo, Stephen P ^a   Reynolds, John ^c   Bhangal, Gurjeet ^a   Smith, Jennifer ^a   McDaid, John P ^a   Tanna, Anisha ^a   Jackson, William D ^a   Masuda, Esteban S ^d   Cook, H Terence ^b   Pusey, Charles D ^a   Tam, Frederick W K ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF BEDFORDSHIRE   (United Kingdom)

^d RIGEL PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; FC RECEPTOR; FOSTAMATINIB; PROTEIN KINASE SYK; OXAZINE DERIVATIVE; PROTEIN TYROSINE KINASE; PYRIDINE DERIVATIVE; SIGNAL PEPTIDE;

ANIMAL CELL; ANTIBODY PRODUCTION; ANTIGEN SPECIFICITY; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; BASEMENT MEMBRANE; BONE MARROW DERIVED MACROPHAGE; CYTOKINE PRODUCTION; ENZYME INHIBITION; ENZYME LINKED IMMUNOSPOT ASSAY; EX VIVO STUDY; FLOW CYTOMETRY; HUMORAL IMMUNITY; IMMUNE MEDIATED INJURY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; KIDNEY DISEASE; KIDNEY FUNCTION; LUNG HEMORRHAGE; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; THERAPY EFFECT; ANIMAL; ANTAGONISTS AND INHIBITORS; ANTI-GLOMERULAR BASEMENT MEMBRANE DISEASE; BLOOD; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; FEMALE; HUMAN; IMMUNOLOGY; METABOLISM; SPLEEN; WISTAR KYOTO RAT;

ANIMALS; ANTI-GLOMERULAR BASEMENT MEMBRANE DISEASE; ANTIBODY FORMATION; AUTOANTIBODIES; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; OXAZINES; PROTEIN-TYROSINE KINASES; PYRIDINES; RATS, INBRED WKY; SPLEEN;

EID: 84921811878     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2013090978     Document Type: Article

References (37)

1. Mócsai A, Ruland J, Tybulewicz VL: The SYK tyrosine kinase: A crucial player in diverse biological functions. Nat Rev Immunol 10: 387-402, 2010
2. Crowley MT, Costello PS, Fitzer-Attas CJ, Turner M, Meng F, Lowell C, Tybulewicz VL, DeFranco AL: A critical role for Syk in signal transduction and phagocytosismediated by Fcgamma receptors onmacrophages. J Exp Med 186: 1027-1039, 1997
3. Kiefer F, Brumell J, Al-Alawi N, Latour S, Cheng A, Veillette A, Grinstein S, Pawson T: The Syk protein tyrosine kinase is essential for Fcgamma receptor signaling in macrophages and neutrophils. Mol Cell Biol 18: 4209-4220, 1998
4. Sedlik C, Orbach D, Veron P, Schweighoffer E, Colucci F, Gamberale R, Ioan-Facsinay A, Verbeek S, Ricciardi-Castagnoli P, Bonnerot C, Tybulewicz VL, Di Santo J, Amigorena S: A critical role for Syk protein tyrosine kinase in Fc receptor-mediated antigen presentation and induction of dendritic cell maturation. J Immunol 170: 846-852, 2003
5. de Castro RO: Regulation and function of syk tyrosine kinase in mast cell signaling and beyond. J Signal Transduct 2011: 507291, 2011
6. Cheng AM, Rowley B, Pao W, Hayday A, Bolen JB, Pawson T: Syk tyrosine kinase required for mouse viability and B-cell development. Nature 378: 303-306, 1995
7. Turner M, Mee PJ, Costello PS, Williams O, Price AA, Duddy LP, Furlong MT, Geahlen RL, Tybulewicz VL: Perinatal lethality and blocked B-cell development in mice lacking the tyrosine kinase Syk. Nature 378: 298-302, 1995
8. Wex E, Bouyssou T, Duechs MJ, Erb KJ, Gantner F, Sanderson MP, Schnapp A, Stierstorfer BE, Wollin L: Induced Syk deletion leads to suppressed allergic responses but has no effect on neutrophil or monocyte migration in vivo. Eur J Immunol 41: 3208-3218, 2011
9. Ruzza P, Biondi B, Calderan A: Therapeutic prospect of Syk inhibitors. Expert Opin Ther Pat 19: 1361-1376, 2009
10. Weinblatt ME, Kavanaugh A, Burgos-Vargas R, Dikranian AH, Medrano-Ramirez G, Morales-Torres JL, Murphy FT, Musser TK, Straniero N, Vicente-Gonzales AV, Grossbard E: Treatment of rheumatoid arthritis with a Syk kinase inhibitor: A twelve-week, randomized, placebo-controlled trial. Arthritis Rheum 58: 3309-3318, 2008
11. Weinblatt ME, Kavanaugh A, Genovese MC, Musser TK, Grossbard EB, Magilavy DB: An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl JMed 363: 1303-1312, 2010
12. Smith J, McDaid JP, Bhangal G, Chawanasuntorapoj R, Masuda ES, Cook HT, Pusey CD, Tam FW: A spleen tyrosine kinase inhibitor reduces the severity of established glomerulonephritis. J Am Soc Nephrol 21: 231-236, 2010
13. Bahjat FR, Pine PR, Reitsma A, Cassafer G, Baluom M, Grillo S, Chang B, Zhao FF, Payan DG, Grossbard EB, Daikh DI: An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus. Arthritis Rheum 58: 1433-1444, 2008
14. DengGM, Liu L, Bahjat FR, Pine PR, TsokosGC: Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus-prone mice. Arthritis Rheum 62: 2086-2092, 2010
15. Braselmann S, Taylor V, Zhao H, Wang S, Sylvain C, Baluom M, Qu K, Herlaar E, Lau A, Young C, Wong BR, Lovell S, Sun T, Park G, Argade A, Jurcevic S, Pine P, Singh R, Grossbard EB, Payan DG, Masuda ES: R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated in flammation. J Pharmacol Exp Ther 319: 998-1008, 2006
16. Pine PR, Chang B, Schoettler N, Banquerigo ML, Wang S, Lau A, Zhao F, Grossbard EB, Payan DG, Brahn E: Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor. Clin Immunol 124: 244-257, 2007
17. Colonna L, Catalano G, Chew C, D'Agati V, Thomas JW, Wong FS, Schmitz J, Masuda ES, Reizis B, Tarakhovsky A, Clynes R: Therapeutic targeting of Syk in autoimmune diabetes. J Immunol 185: 1532-1543, 2010
18. Ryan JJ, Reynolds J, Norgan VA, Pusey CD: Expression and characterization of recombinant rat alpha 3(IV)NC1 and its use in induction of experimental autoimmune glomerulonephritis. Nephrol Dial Transplant 16: 253-261, 2001
19. Reynolds J, Abbott DS, Karegli J, Evans DJ, Pusey CD: Mucosal tolerance induced by an immunodominant peptide from rat alpha3(IV)NC1 in established experimental autoimmune glomerulonephritis. Am J Pathol 174: 2202-2210, 2009
20. Pedchenko V, Bondar O, Fogo AB, Vanacore R, Voziyan P, Kitching AR, Wieslander J, Kashtan C, Borza DB, Neilson EG, Wilson CB, Hudson BG: Molecular architecture of the Goodpasture autoantigen in anti-GBM nephritis. N Engl J Med 363: 343-354, 2010
21. Reynolds J, Moss J, Duda MA, Smith J, Karkar AM, Macherla V, Shore I, Evans DJ, Woodrow DF, Pusey CD: The evolution of crescentic nephritis and alveolar haemorrhage following induction of autoimmunity to glomerular basement membrane in an experimental model of Goodpasture's disease. J Pathol 200: 118-129, 2003
22. Pusey CD: Anti-glomerular basement membrane disease. Kidney Int 64: 1535-1550, 2003
23. Kim MJ, McDaid JP, McAdoo SP, Barratt J, Molyneux K, Masuda ES, Pusey CD, Tam FW: Spleen tyrosine kinase is important in the production of proinflammatory cytokines and cell proliferation in human mesangial cells following stimulation with IgA1 isolated from IgA nephropathy patients. J Immunol 189: 3751-3758, 2012
24. Khan SB, Cook HT, Bhangal G, Smith J, Tam FW, Pusey CD: Antibody blockade of TNF-alpha reduces inflammation and scarring in experimental crescentic glomerulonephritis. Kidney Int 67: 1812-1820, 2005
25. Kitching AR, Tipping PG, Holdsworth SR: IL-12 directs severe renal injury, crescent formation and Th1 responses in murine glomerulonephritis. Eur J Immunol 29: 1-10, 1999
26. Smith J, Lai PC, Behmoaras J, Roufosse C, Bhangal G, McDaid JP, Aitman T, Tam FW, Pusey CD, Cook HT: Genes expressed by both mesangial cells and bone marrow-derived cells underlie genetic susceptibility to crescentic glomerulonephritis in the rat. J Am Soc Nephrol 18: 1816-1823, 2007
27. Ryan J, Ma FY, Kanellis J, Delgado M, Blease K, Nikolic-Paterson DJ: Spleen tyrosine kinase promotes acute neutrophil-mediated glomerular injury via activation of JNK and p38 MAPK in rat nephrotoxic serum nephritis. Lab Invest 91: 1727-1738, 2011
28. Duffield JS: Macrophages and immunologic inflammation of the kidney. Semin Nephrol 30: 234-254, 2010
29. Ozaki N, Suzuki S, Ishida M, Harada Y, Tanaka K, Sato Y, Kono T, Kubo M, Kitamura D, Encinas J, Hara H, Yoshida H: Syk-dependent signaling pathways in neutrophils and macrophages are indispensable in the pathogenesis of anti-collagen antibody-induced arthritis. Int Immunol 24: 539-550, 2012
30. Timoshanko JR, Kitching AR, Holdsworth SR, Tipping PG: Interleukin- 12 from intrinsic cells is an effector of renal injury in crescentic glomerulonephritis. J Am Soc Nephrol 12: 464-471, 2001
31. Colby TV, Fukuoka J, Ewaskow SP, Helmers R, Leslie KO: Pathologic approach to pulmonary hemorrhage. Ann Diagn Pathol 5: 309-319, 2001
32. Mayadas TN, Rosetti F, Ernandez T, Sethi S: Neutrophils: Game changers in glomerulonephritis? Trends Mol Med 16: 368-378, 2010
33. Holdsworth SR, Summers SA: Role of mast cells in progressive renal diseases. J Am Soc Nephrol 19: 2254-2261, 2008
34. Hochheiser K, Engel DR, Hammerich L, Heymann F, Knolle PA, Panzer U, Kurts C: Kidney dendritic cells become pathogenic during crescentic glomerulonephritis with proteinuria. J Am Soc Nephrol 22: 306-316, 2011
35. Podolanczuk A, Lazarus AH, Crow AR, Grossbard E, Bussel JB: Of mice and men: An open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk. Blood 113: 3154-3160, 2009
36. Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A, Schaefer-Cutillo J, De Vos S, Sinha R, Leonard JP, Cripe LD, Gregory SA, Sterba MP, Lowe AM, Levy R, Shipp MA: Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkinlymphoma and chronic lymphocytic leukemia. Blood 115: 2578-2585, 2010
37. Sheryanna A, Bhangal G, McDaid J, Smith J, Manning A, Foxwell BM, Feldmann M, Cook HT, Pusey CD, Tam FW: Inhibition of p38 mitogenactivated protein kinase is effective in the treatment of experimental crescentic glomerulonephritis and suppressesmonocyte chemoattractant protein-1 but not IL-1beta or IL-6. J AmSoc Nephrol 18: 1167-1179, 2007